<DOC>
	<DOCNO>NCT02254226</DOCNO>
	<brief_summary>1 . To compare systemic drug exposure 100 μg Serevent ® Diskus ® 50 μg Serevent ® MDI sufficient precision combination second trial demonstrate systemic drug exposure new formulation salmeterol xinafoate superior Serevent ® MDI 2 . To test system order null hypothesis regard exposure two dose level Serevent ® Diskus ® Serevent ® MDI 3 . To get data systemic drug exposure 25 μg Serevent ® MDI 50 μg Serevent ® Diskus ®</brief_summary>
	<brief_title>Pharmacokinetics Salmeterol ( Serevent® ) After Inhalation With Metered Dose Inhaler ( MDI ) Diskus® Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead ECG ( electrocardiogram ) , clinical laboratory test 1.1 No find deviate normal clinical relevance 1.2 No evidence clinically relevant concomitant disease 2 . Age ≥21 ≤50 year 3 . BMI ≥18.5 &lt; 30 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Surgery gastrointestinal tract ( except appendectomy ) 3 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 4 . History relevant orthostatic hypotension , faint spell blackout . 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 7 . Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives respective drug prior administration trial . 8 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial . 9 . Participation another trial investigational drug within 2 month prior administration trial . 10 . Smoker ( 10 cigarette three cigar three pipe per day ) 11 . Inability refrain smoke trial day 12 . Alcohol abuse ( 60 g/day ) 13 . Drug abuse 14 . Blood donation ( 100 mL within 4 week prior administration trial ) 15 . Excessive physical activity ( within 1 week prior administration trial ) 16 . Any laboratory value outside reference range clinical relevance 17 . Inability comply dietary regimen study centre Exclusion criterion specific study : 18 . Asthma history pulmonary hyperreactivity 19 . Allergy / hypersensitivity Lactose monohydrate 20 . Hyperthyrosis 21 . Allergic rhinitis need treatment 22 . Cardiac arrhythmia 23 . Paroxysmal tachycardia ( &gt; 100 beat per minute ) 24 . Aortic stenosis</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>